High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen

AIDS

Volumn 27, Issue 18, 2013, Pages 2893-2897

  Cachay, Edward R ^a   Wyles, David L ^a   Torriani, Francesca J ^a   Ballard, Craig ^b   Colwell, Bradford ^b   Lin, Jennifer C ^a   Hill, Lucas ^b   Mathews, William C ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adverse events; Hepatitis C virus; HIV; Telaprevir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; MARAVIROC; PEGINTERFERON; RALTEGRAVIR; RIBAVIRIN; TELAPREVIR; TENOFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ADULT; ANEMIA; ARTICLE; ASCITES; BRAIN DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; LUNG ABSCESS; MALE; MENTAL DISEASE; MIXED INFECTION; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; RELAPSE; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; UROSEPSIS; COMPLICATION; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; INCIDENCE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT WITHDRAWAL; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; UNITED STATES; WITHHOLDING TREATMENT;

EID: 84888288310     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000432466.15885.14     Document Type: Article

References (8)

1. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Manhke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. Ann Intern Med 2013; 159:86-96.
2. National Institute of Health. Division of AIDS table for Grading the Severity of Adult and Pediatric Adverse Events. http://rsc. tech-res.com/ safetyandpharmacovigilance/gradingtables.aspx. [Accessed 19 November 2012].
3. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002; 97:1183-1194.
4. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
5. Ramamurthy M, Muir AJ. Treatment of hepatitis C in special populations. Clin Liver Dis 2006; 10:851-865.
6. Sulkowski MS, Roberts S, Afdhal N, Andreone P, Diago M, Pol S, et al. Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract 1162.]. In: Poster and abstracts of the 47th International Liver Congress (EASL 2012), Barcelona; 2012.
7. Hezode, C Dorival, F Zoulim, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First Results of the French Early Access Program (ANRS CO20-CUPIC) [Abstract 8.]. In: Poster and abstracts of the 47th International Liver Congress (EASL 2012), Barcelona; 2012.
8. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik K, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world. PLos One 2013; 8:e55285.